Synthetic nicotine analogues to evade rules? The case of 6-methylnicotine

(S)-6-Methylnicotine (6MN), a synthetic nicotine analogue with a methyl group at the 6-position of the pyridine ring, has recently gained attention due to its use in e-cigarettes marketed as alternatives to conventional nicotine products. This strategy has allowed manufacturers to circumvent regulatory oversight, prompting scrutiny from the Food and Drug Administration and other health authorities. About pharmacological and toxicological profile, a limited number of studies suggest that 6MN exhibits greater potency and toxicity than (S)-nicotine, with potential public health implications, particularly for younger populations. While manufacturers claim safety and regulatory exemptions for products containing 6MN, such as SPREE BAR, independent evaluations are lacking. Preliminary data indicate similar efficacy and safety patterns between 6MN and nicotine, though concerns about chronic inhalation risks persist. The emergence and spread of nicotine analogues highlight an urgent need for comprehensive regulatory frameworks and independent and in-depth toxicological studies to safeguard public health.